For patients at risk of plasma cell disorders, early identification is critical to ensure better outcomes. Coined as MASS-FIX, our innovative approach uses matrix-assisted laser desorption/ionization-time of flight mass spectrometry (MALDI-TOF MS), and marks the first major breakthrough in multiple myeloma screening since electrophoresis was developed in 1967.
Arming providers with accurate testing for monitoring patients
Since the early 2000s, the average length of survival from time of diagnosis has more than tripled to more than five years.
The Most Accurate Testing for Monitoring
The new MALDI-TOF MS testing method provides:
- Increased sensitivity for early identification of myeloma relapse.
- Verification if monoclonal therapeutics or residual disease caused the IgG kappa mass.
- Potential to prevent unnecessary bone marrow biopsies.
- Convenient, cost-effective, and clinically relevant information.
- Industry-leading turnaround times for results.
Which test should I order?
A Test in Focus
David Murray, M.D., Ph.D., provides an overview of the updated monoclonal gammopathy screening and monitoring tests for multiple myeloma. He discusses when this testing should be ordered, how this approach improves upon previous methods, and what clinical action can be taken from the results of these tests.
Minimal Residual Disease (MRD) Testing
As more effective therapies have become available, the average overall survival length for newly diagnosed multiple myeloma patients has more than tripled since the early 2000s. Detecting minimal residual disease in bone marrow samples during treatment or after therapy has become increasingly important. Patients who do not achieve a minimal residual disease (MRD) negative status and will relapse faster and have a shorter survival length.
With a sensitivity of 10(-5), our EuroFlow MRD test meets the guidelines recommended by the International Myeloma Working Group (IMWG), the National Comprehensive Cancer Network (NCCN), and the International Clinical Cytometry Society. Additionally, because most clinical trials require the
use of MRD testing with at least a 10(-5) sensitivity, approaches that overcome the current limitations of conventional flow cytometry must be used.